Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Projected to Strengthen in Value and Scale by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Predicted Market Size and CAGR of the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market by the End of the 2029?
The investigational new drug contract development and manufacturing organization (CDMO) market size has grown strongly in recent years. It will grow from $5.53 billion in 2024 to $5.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising demand for early-phase clinical trials, increasing outsourcing by pharmaceutical companies, a rise in biologics and complex molecule development, growing regulatory support for accelerated drug approvals, and increasing focus on cost-efficiency and speed-to-market.
The investigational new drug contract development and manufacturing organization (CDMO) market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to expanding focus on rare and orphan drug development, increasing need for integrated preclinical-to-clinical services, rise in complexity of biologics and gene therapies, growing investment in small molecule innovation, and increasing adoption of virtual pharma business models. Major trends in the forecast period include advancements in integrated drug development platforms, the development of AI-driven clinical trial designs, innovation in personalized medicine manufacturing, advancements in regulatory compliance technologies, and the development of flexible and modular manufacturing facilities.
Get your free report sample today:
What Are the Significant Market Forces Driving the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Performance?
The rising clinical trials are expected to propel the growth of the investigational new drug contract development and manufacturing organization (CDMO) market going forward. Clinical trials are carefully designed studies involving human participants to test how safe and effective a medical treatment, procedure, or intervention is under controlled conditions. The rise in clinical trials is largely driven by the growing demand for innovative treatments, as increasing rates of chronic and complex diseases push pharmaceutical and biotech companies to develop and test new therapies. Investigational new drug CDMOs support clinical trials by streamlining the development and manufacturing of trial-ready drug formulations, ensuring a timely and compliant supply of investigational products for each study phase. For instance, in November 2023, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the UK saw a 4.3% increase in the yearly number of industry-led clinical trials, growing from 394 in 2021 to 411 in 2022. Therefore, the rising clinical trials are driving the growth of the investigational new drug contract development and manufacturing organization (CDMO) market.
Which Segments Are Likely to Shape the Future Outlook of the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Small Molecules, Large Molecules
2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations
3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services
4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides
2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics
Which Major Trends Are Expected to Define the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Through 2029?
Major companies operating in the investigational new drug contract development and manufacturing organization (CDMO) market are focusing on strategic partnerships to strengthen development capabilities and speed up clinical entry. Strategic partnerships refer to formal alliances between two or more organizations that collaborate to achieve shared objectives, leveraging each other’s strengths, resources, or expertise to gain mutual benefits while remaining independent entities. For instance, in August 2023, Sartorius AG, a Germany-based life science company, partnered with Repligen Corporation, a US-based life sciences company, to launch an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This collaboration aims to streamline biopharmaceutical production by enhancing efficiency and scalability. The initiative marks Sartorius’ continued innovation in bioprocessing solutions, reinforcing its commitment to advancing the biomanufacturing industry.
Which Major Organizations Influence the Direction of the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.
Get the detailed investigational new drug contract development and manufacturing organization (cdmo) market report today
Which Region Holds the Largest Share of the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment